Neutral - Price 4.60 on Nov. 27 by Jesup & Lamont Akeena is in a large growth phase with estimated revenue growth of 86% year over year for '08....Balancing strong revenue growth prospects with uncertainty surrounding its new technology, we believe Akeena is fairly valued at $4.60 a share, 1.7 times our 2008 revenue estimate on an enterprise-value basis. Market cap: $128 million.

Market Perform/Speculative Risk - Price 50.65 on Nov. 27 by Rodman & Renshaw ATRO makes aerospace systems. We believe it provides a compelling long-term investment opportunity [owing to]...1) a focus on niche markets such as lighting, in-flight power and entertainment systems; 2) growing backlog of $90 million/revenue visibility...into FY08; 3) initiative to become a systems provider versus component manufacturer; 4) increasing institutional ownership; 5) recent share-price appreciation...[which could help] the balance sheet and better capitalize ATRO....Market cap: $436 million.

Hold - Price 3.07 on Nov. 27 by Wedbush Morgan This retailer of home furnishings, accessories, and gourmet foods and beverages, including beer and wine, has 296 stores in 34 states. We are lowering our target to 4, from 6....The difficult housing market is hurting sales of home furnishing, as [is] the credit crunch. Market cap: $68 million.

Outperform - Price 12 on Nov. 27 by Fox-Pitt Kelton Cochran Caronia Waller We recently met with senior management of Dime and walked away more confident about how the business is being managed in a difficult environment. We would classify its balance-sheet management as risk-averse with above-average tangible capital (6.61%, versus 4.75% to 5.5% for peers) and limited credit risk (5 basis points of [nonperforming assets/assets])...Target: 16. Market cap: $409 million.

Buy - Price 46.93 on Nov. 21 by Singular Research MDR reported total revenue of $1.32 billion, $15.5 million above our estimate -- [an increase of] 18.4% year over year...Revenue from offshore oil-and-gas construction segment increased 32.3% y/o/y from $440.2 million to $582.2 million...At end of Q307, MDR's total backlog grew 8.1%, from $8.6 billion in Q306 to $9.3 billion, a sequential increase of 4.4%. Maintaining our Q407 revenue estimate of $1.52 billion and EPS estimate of 56 cents. Maintaining 70 target and Buy rating. Market cap: $10.8 billion.

Buy - Price 2.60 on Nov. 27 by Merriman Curhan Ford NTII [has] successfully completed a $60 million secondary offering [for completing]...pivotal Phase 3 trials of Viprinex for treatment of acute ischemic stroke. NTII also receives milestone fees and royalty payments on net sales of Forest Laboratories' Namenda [among others]...Based on our FY12 EPS estimate of $2.90, a conservative 60% discount rate and price/earnings ratio range of 20 to 25 times, we estimate current fair value of 11 to 13...conservatively assuming FY12 Viprinex sales of less than $250 million, [or] market-penetration rate of less than 8%. Market cap: $69 million.

Buy - Price 89.46 on Nov. 26 by UBS Securities Following recent meetings with PRU [and] CEO Art Ryan, we remain confident that PRU will meet or exceed its 15% to 17% [return-on-equity] target for '07-'09, supported by faster growth in higher-ROE businesses, including asset management, international and retirement, and capital redeployment. Target: 117. Market cap: $40.6 billion.

Outperform - Price 38.86 on Nov. 26 by RBC Capital Markets Our 42 target is based on a forecast 12-month dividend distribution one year forward of $1.50, and a required dividend yield of 3.6%. We estimate that a 10-basis-point change in the required dividend yield would impact our price target by approximately $1.25 per share. Market cap: $20.9 billion.